interleukin 6

MA gears up growth mergers buyout strategy
Biotech

Tiziana to spin out IL-6 drug, cites pharma interest in modality

Tiziana has pointed to increased Big Pharma interest in the IL-6 pathway as justification for spinning out its own candidate into a separate company.
James Waldron Dec 2, 2025 8:45am
A chessboard with blocks that read MA

Novartis spends $1.4B for Tourmaline, CV med that wowed in ph. 2

Sep 9, 2025 4:28am
IBD

I-Mab's IL-6 drug hits goal in ulcerative colitis phase 2

Apr 26, 2021 8:45am
Lung Fibrosis

Lassen Therapeutics, Cedars Sinai team up on lung fibrosis work

Mar 25, 2021 9:20am
Roche

Roche test OK’d to identify high-risk COVID-19 patients

Jun 4, 2020 10:50am